Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Molecules that are able to inhibit the binding between NGF and the TrkA receptor as analgesics with prolonged effect

Molecules that are able to inhibit the binding between NGF and the TrkA receptor as analgesics with prolonged effect

US Patent 9688749 · Granted Jun 27, 2017

Estimated economic value: $159,595,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Intrabodies targeting post-translational modifications of native proteins and me2021
Therapeutic use of the botulinum neurotoxin serotype A2020
Anti-TrkA antibodies, derivatives and uses thereof2016
Polynucleotides encoding humanized anti-NGF antibodies2014
Method for the potentiation of opioid analgesics effects on pain2014
Method for the potentiation of opioid analgesics effects on pain2014
Analgesic treatment with prolonged effect2014
Analgesic treatment with prolonged effect2014
Method for the humanization of antibodies and humanized antibodies thereby obtai2012
Method for the treatment of pain with humanized anti-nerve growth factor antibod2012
Humanized anti-nerve growth factor antibodies2012
Method for the potentiation of opioid analgesics effects on pain2011